Patents by Inventor Peter Turecek

Peter Turecek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE
    Publication number: 20140121351
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Application
    Filed: December 20, 2013
    Publication date: May 1, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: Stefan Haider, Andreas Ivens, Hanspeter Rottensteiner, Juregen Siekmann, Peter Turecek
  • Composition exhibiting a von Willebrand Factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
    Patent number: 8703429
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: April 22, 2014
    Assignee: Baxler Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Composition exhibiting a von Willebrand Factor (vWF) protease activity with the amino acid sequence AAGGILHLELLV
    Patent number: 8703426
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: April 22, 2014
    Assignee: Baxter Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • BLOOD COAGULATION PROTEIN CONJUGATES
    Publication number: 20140107320
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 17, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: Stefan Haider, Hanspeter Rottensteiner, Juergen Siekmann, Peter Turecek
  • Method and Compositions for Specifically Detecting Physiologically Acceptable Polymer Molecules
    Publication number: 20140051094
    Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.
    Type: Application
    Filed: September 13, 2013
    Publication date: February 20, 2014
    Applicants: Baxter Healthcare SA, Baxter International Inc.
    Inventors: Peter Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Varadi, Susanne Vejda
  • Methods for Treating Bleeding Disorders
    Publication number: 20140050717
    Abstract: A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor X1; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor X1-dependent manner.
    Type: Application
    Filed: August 29, 2013
    Publication date: February 20, 2014
    Inventors: Michael Dockal, Friedrich Scheiflinger, Peter Turecek
  • Nucleophilic catalysts for oxime linkage
    Patent number: 8642737
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: February 4, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Andreas Ivens, Peter Turecek, Oliver Zoechling
  • Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life
    Patent number: 8637007
    Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: January 28, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Marie-Christine Canavaggio
  • Blood coagulation protein conjugates
    Patent number: 8637640
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: January 28, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Method for testing treatment of ADAMTS13 deficiency
    Patent number: 8623612
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: January 7, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE
    Publication number: 20130296243
    Abstract: The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.
    Type: Application
    Filed: April 11, 2013
    Publication date: November 7, 2013
    Inventors: Hans-Peter Schwarz, Peter Turecek
  • Method and compositions for specifically detecting physiologically acceptable polymer molecules
    Patent number: 8557534
    Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: October 15, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Varadi, Susanne Vejda
  • Factor VIII polypeptide having factor VIII:C activity
    Patent number: 8546332
    Abstract: Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: October 1, 2013
    Assignee: Stichting Sanquin Bloedvoorziening
    Inventors: Petrus Johannes Lenting, Jan Aart Van Mourik, Koenraad Mertens, Hans Pannekoek, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger
  • Method for identifying a non-anticoagulant sulfated polysaccharide which enhances blood coagulation dependence on FXI
    Patent number: 8546096
    Abstract: A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence of FXI, the method comprising: a) combining a blood or plasma sample having activation competent FXI with a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient In activation competent FXI with a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: October 1, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Michael Dockal, Friedrich Scheiflinger, Peter Turecek
  • METHODS OF MEASURING ADAMTS 13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF
    Publication number: 20130252263
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 26, 2013
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • Hydrolysable polymeric FMOC-linker
    Patent number: 8445544
    Abstract: The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: May 21, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Peter Turecek, Juergen Siekmann
  • Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof
    Patent number: 8415114
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: April 9, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • KIT FOR MEASURING THE THROMBIN GENERATION IN A SAMPLE OF A SAMPLE OF A PATIENT'S BLOOD OR PLASMA
    Publication number: 20130052672
    Abstract: The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl2. The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.
    Type: Application
    Filed: June 29, 2012
    Publication date: February 28, 2013
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Katalin Varadi, Peter Turecek, Brigitte Keil, Sylvia Peyrer-Heimstaett, Hans-Peter Schwarz
  • Methods of Determining Polydispersity and/or Molecular Weight Distribution of a Polyethylene Glycol Sample
    Publication number: 20130043383
    Abstract: Disclosed herein are methods of determining polydispersity (PDI) and molecular mass distribution (MMD) of reactive PEG samples using mass spectrometry. More specifically, a mass spectrometry method called GEMMA is used to determine PDI and MMD of PEG samples which provides more accurate measurements for high molecular weight PEG samples than prior known MALDI-TOF analysis.
    Type: Application
    Filed: March 21, 2012
    Publication date: February 21, 2013
    Applicants: BAXTER HEALTHCARE S. A., TECHNISCHE UNIVERSITAET WIEN, BAXTER INTERNATIONAL INC.
    Inventors: Jasmin Kemptner, Martina Marchetti-Deschmann, Juergen Siekmann, Peter Turecek, Hans-Peter Schwarz, Guenter Allmaier
  • Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
    Patent number: 8377375
    Abstract: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: February 19, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Heinz Anderle, Peter Matthiessen, Hans-Peter Schwarz, Peter Turecek, Thomas Kreil, Daniel R. Boggs